AROMATIC COMPOUND, METHOD OF ITS PRODUCTION AND ITS USE FOR OBTAINING AN ESTROGEN RECEPTOR DESTRUCTOR

Claims

1. A compound represented by formula (I), or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof: Where R 1 selected from the group consisting of H, C1-C6 alkyl, hydroxyl, amino, carboxyl, C1-C6 alkoxy, dihydroxyboranyl and -OR'; R' is selected from the group consisting of phenyl and benzyl; R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; provided that the dotted line in the benzene ring represents a bond, R 3 and R 4 independently selected from absence; provided that the dotted line in the benzene ring is absent, each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5 selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; n is 0, 1, or 2; R 6represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; provided that there is no dotted line between Y and W, W is NH and Y is halogen; provided that the dotted line between Y and W represents a bond, W represents N; and Y is selected from the group consisting of none, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; R 21selected from the group consisting of, provided that the dotted line between Y and W is absent, W is NH, and Y is halogen; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; The heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2, or 3.

2. The compound according to claim 1 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (II): Where R 1 selected from the group consisting of H, C1-C6 alkyl, hydroxyl, amino, carboxyl, C1-C6 alkoxy, dihydroxyboranyl and -OR'; R' is selected from the group consisting of phenyl and benzyl; R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; provided that the dotted line in the benzene ring represents a bond, R 3 and R 4 independently selected from absence; provided that the dotted line in the benzene ring is absent, each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; n is 0, 1, or 2; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; The heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2, or 3.

3. The compound according to claim 2 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (III): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; provided that the dotted line in the benzene ring represents a bond, R 3 and R 4 independently selected from absence; provided that the dotted line in the benzene ring is absent, each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; n is 0, 1, or 2; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CRY1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

4. The compound according to claim 3 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (IV): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5 selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; n is 0, 1, or 2; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

5. The compound according to claim 4 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (V): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5 is selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl, and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; n is 0, 1, or 2; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, C1-C6 alkoxy; alternatively, any two E 3are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

6. The compound according to claim 5 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (VI): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5 selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

7. The compound according to claim 6 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (VII): Where each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5 selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

8. The compound according to claim 7 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (VIII): Where each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10independently selected from the group consisting of H and C1-C6 alkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5is selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

9. The compound according to claim 7 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (IX): Where each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2 and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

10. The compound according to claim 9 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (X): Where each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2 and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

11. The compound according to claim 6 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XI): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 , R 4independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 11 represents a substituent at any position of the benzene ring, and d represents the number of substituents R 11 ; each R 11 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; d is 0, 1, 2 or 3; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

12. The compound according to claim 11 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XII): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 11 represents a substituent at any position of the benzene ring, and d represents the number of substituents R 11 ; each R 11 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; d is 0, 1, 2 or 3; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; R 12 selected from the group consisting of H, halogen, C1-C6 alkyl and hydroxyl; each of m1, m2, m3, m4, m5, m6 is independently selected from the group consisting of 0, 1, 2 or 3; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl.

13. The compound according to claim 12 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XIII): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 11 represents a substituent at any position of the benzene ring, and d represents the number of substituents R 11 ; each R 11 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; d is 0, 1, 2 or 3; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; R 12 selected from the group consisting of H, halogen, C1-C6 alkyl and hydroxyl; each of m1, m2, m3, m4, m5, m6 is independently selected from the group consisting of 0, 1, 2 or 3; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; and the number of heteroatoms is 1, 2, or 3; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2 and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl.

14. The compound according to claim 12 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XIV): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 11 represents a substituent at any position of the benzene ring, and d represents the number of substituents R 11 ; each R 11 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; d is 0, 1, 2 or 3; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; R 12 selected from the group consisting of H, halogen, C1-C6 alkyl and hydroxyl; each of m1, m2, m3, m4, m5, m6 is independently selected from the group consisting of 0, 1, 2 or 3; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl.

15. The compound according to claim 6 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XV): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 11 represents a substituent at any position of the thiophene ring, and d represents the number of substituents R 11 ; each R 11 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; d is 0, 1, 2 or 3; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

16. The compound according to claim 6 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XVI): Where R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; R 11 represents a substituent at any position of the thiophene ring, and d represents the number of substituents R 11 ; each R 11 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; d is 0, 1, 2 or 3; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

17. The compound according to claim 2 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XVII): Where each of R 3 and R 4 independently selected from the group consisting of H and C1-C6 alkyl; alternatively, R 3 and R 4 connected to form a 3-6-membered cycloalkyl; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 11 represents a substituent at any position of the benzene ring, and d represents the number of substituents R 11 ; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; d is 0, 1, 2, or 3; b is 0, 1, 2, or 3; and at least one of d and b is not equal to 0; each of R 11 and R 6 is independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl and C1-C6 alkoxy; and at least one of them is fluorine; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

18. The compound according to claim 17 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XVIII): Where X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 11represents a substituent at any position of the benzene ring, and d represents the number of substituents R 11 ; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; d is 0, 1, 2, or 3; b is 0, 1, 2, or 3; and at least one of d and b is not equal to 0; each of R 11 and R 6 is independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl and C1-C6 alkoxy; and at least one of them is fluorine; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence and CR 9 R 10 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, X is selected from the group consisting of CH2, CF2, or O; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

19. The compound according to claim 2 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XIX): Where R 1 selected from the group consisting of H, C1-C6 alkyl, hydroxyl, amino or C1-C6 alkoxy and dihydroxyboranyl; R 2 represents a substituent at any position of the benzene ring, and a represents the number of substituents R 2 ; each R 2 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; a is equal to 0, 1, 2 or 3; R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; n is 0, 1, or 2; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; E 3 represents a substituent at any position of the benzene ring, and c represents the number of substituents E 3 ; every E 3 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; alternatively, any two E 3 are connected to form a 3-6-membered cycloalkyl, a 6-10-membered aryl, a 4-12-membered heterocycloalkyl and a 5-8-membered heteroaryl; c is 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy.

20. The compound according to claim 19 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XX): Where R 5selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted 6-10-membered aryl and substituted or unsubstituted 5-8-membered heteroaryl; the aryl or heteroaryl substituent is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl and C1-C6 alkoxy; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR 7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; each ring A and ring B is independently selected from the group consisting of 4-12 membered cycloalkyl and 4-12 membered heterocycloalkyl; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR 11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; the heteroatom in the heteroaryl is selected from the group consisting of O, N or S; the number of heteroatoms is 1, 2 or 3; the heteroatom in heterocycloaryl is N; the number of heteroatoms is 1, 2 or 3; preferably, R 5 selected from the group consisting of C1-C6 alkyl, 3-6-membered cycloalkyl, trifluoromethyl, trifluoroethyl, substituted or unsubstituted phenyl, substituted or unsubstituted thienyl, substituted or unsubstituted furanyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted pyrazolyl, and substituted or unsubstituted pyrazinyl; the substituent of said phenyl, thienyl, furanyl, pyrrolyl, pyrimidinyl, pyridazinyl, pyrazolyl, or pyrazinyl is selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; X is selected from the group consisting of CH2, CF2, O, S, SO, SO2, and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6 membered cycloalkyl; Ring A and Ring B are each independently selected from the group consisting of 4- to 12-membered cycloalkyl and 4- to 12-membered heterocycloalkyl; provided that both Ring A and Ring B are heterocycloalkyl, one of the rings contains one N heteroatom and the other ring contains two N heteroatoms.

21. The compound according to claim 20 or its optical isomer, or its salt, or its hydrate, or its solvate, characterized in that the compound is represented by formula (XXI): Where R 11 represents a substituent at any position of the benzene ring, and d represents the number of substituents R 11 ; each R 11 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6-membered cycloalkyl, and C1-C6 alkoxy; d is 0, 1, 2 or 3; X is selected from the group consisting of CR 7 R 8 , O, S, SO, SO2 and NR7 ; each of R 7 and R 8 independently selected from the group consisting of H, halogen, C1-C6 alkyl, and 3-6 membered cycloalkyl; R 6 represents a substituent at any position of the benzene ring, and b represents the number of substituents R 6 ; each R 6 independently selected from the group consisting of halogen, hydroxyl, amino, cyano, trifluoromethyl, C1-C6 alkyl, 3-6 membered cycloalkyl, and C1-C6 alkoxy; b is equal to 0, 1, 2 or 3; M is selected from the group consisting of absence, CR 9 R 10 , O, S, SO, SO2 and NR 9 ; each of R 9 and R 10 independently selected from the group consisting of H and C1-C6 alkyl; each of m1, m2, m3, m4, m5 and m6 is independently selected from the group consisting of 0, 1, 2 or 3; Y is selected from the group consisting of absence, CR Y1 R Y2 , C(O), -CR 11 =CR 12 -, -CR11 =N-, -N=N- and -OC(O)-; each of R Y1 and R Y2 independently selected from the group consisting of H and C1-C6 alkyl; each of R 11 and R 12 independently selected from the group consisting of H and C1-C6 alkyl; preferably, X is selected from the group consisting of CH2, CF2, O, S, SO, SO2 and NR 7 ; R 7 selected from the group consisting of H, halogen, C1-C6 alkyl and 3-6-membered cycloalkyl.

22. A compound according to any one of paragraphs 1-11 or 15-20, or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof, characterized in that each of said ring A and ring B is independently selected from the group consisting of the following structures:

23. A compound according to any one of paragraphs 1-21, or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof, characterized in that said selected from the group consisting of the following structures:

24. A compound according to any one of paragraphs 1-21, or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof, characterized in that said compound is selected from the group consisting of the following compounds:

25. The compound according to any one of claims 1 to 21, or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof, wherein the salt is a pharmaceutically acceptable salt; the pharmaceutically acceptable salt is a phosphate, D-camphorsulfonate, hydrochloride, hydrobromide, hydrofluoride, sulfate, nitrate, formate, acetate, propionate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, tartrate, citrate, picrate, mesylate, phenylmethanesulfonate, benzenesulfonate, aspartate or glutamate compound.

26. Use of a compound according to any one of claims 1-25 or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof for the production of estrogen receptor destructors.

27. Use of a compound according to any one of claims 1 to 25 or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof for the production of medicinal products for the treatment of diseases associated with the estrogen receptor.

28. Use of a compound according to any one of claims 1-25 or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof for the production of medicinal products for the treatment and / or prevention of cancer.

29. Use of a compound according to any one of claims 1-25 or an optical isomer thereof, or a salt thereof, or a hydrate thereof, or a solvate thereof for the production of medicinal products for the treatment and / or prevention of bone cancer, colorectal cancer, endometrial cancer, prostate cancer, ovarian cancer, uterine cancer, cervical cancer, lung cancer and breast cancer.

30. A medicinal product for the treatment of cancer, characterized in that it is obtained by using a compound according to any one of claims 1-25 or its optical isomer, or its salt, or its hydrate, or its solvate as active ingredients in combination with pharmaceutically acceptable excipients.